Drug intelligence / Profile preview

CKD-385

Development stage: Phase 1
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

CKD-385 is an orally administered small molecule drug candidate developed by Chong Kun Dang Pharmaceutical. It is classified as an antihyperlipidaemic, antihypertensive, and cardiovascular therapy agent. The drug has been investigated for the treatment of progressive hypertension, heart failure, angina pectoris, and other cardiovascular disorders. As of the latest available information, its mechanism of action remains undefined. CKD-385 is considered a new molecular entity and has not yet advanced beyond early clinical development phases[1][2].

Beyond the preview

Go deeper on CKD-385.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CKD-385.

Explore the full profile